Vanadium Complexes for Mitochondria‐Targeted Photodynamic Therapy

Abstract Metal‐based drugs have the potential to significantly improve therapeutic efficacy by exhibiting key properties such as appropriate charge, thermodynamic stability, hydrolytic stability, oral bioavailability, and dual functional capability. These properties are critical for effective intracellular uptake, as drugs or prodrugs must cross cellular membranes to target specific organelles like mitochondria, essential for maximizing therapeutic impact. Bio‐essential metal ions such as copper, zinc, and iron are transported through specialized active channels, whereas others depend on passive diffusion to enter cells. Vanadium has gained significant attention in research because of its remarkable coordination flexibility, lipid‐lowering characteristics, and potential anticancer effects. The coordination flexibility of vanadium has led to its investigation in pharmaceuticals, given its demonstrated insulin‐mimetic effects, lipid‐lowering properties, and promising antitumor activities. Photodynamic therapy (PDT) offers a targeted cancer treatment approach through light‐activated compounds that selectively generate reactive oxygen species (ROS) to induce cell death. Among metal‐based photosensitizers, vanadium complexes are emerging as effective agents due to their unique redox properties and known biological activity. This minireview explores mitochondria‐targeting vanadium complexes within PDT. Mitochondria serve as an ideal ROS generation site, triggering apoptosis while minimizing damage to healthy cells. We examine key strategies in designing vanadium complexes that enhance mitochondrial localization, photodynamic efficiency, and cytotoxic effects on cancer cells. This review highlights the challenges like photostability and selective targeting, and future directions for advancing vanadium‐based photosensitizers as next‐generation PDT cancer therapies.